INTERMEZZO
LOE ApproachingNDASUBLINGUALTABLET
Approved
Nov 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTERMEZZO is a sublingual tablet approved in 2011 for an undisclosed indication via Purdue Pharma. The exact mechanism of action and therapeutic class remain unspecified in available data. The drug represents a niche formulation innovation in the sublingual delivery space.
LOE Approaching2.8 years to LOE
Product approaching loss of exclusivity within ~2.8 years with minimal public commercial data, suggesting small-to-mid-size commercial footprint requiring defensive strategy planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on INTERMEZZO at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.